Analysts’ recommendations and target price

Wall Street analysts have given Johnson & Johnson (JNJ) a 12-month consensus target price of $144.71, 5.50% higher than the company’s closing price on March 18. The consensus analyst recommendation for the stock is a “buy.” Although analysts first revised the company’s target price downward from $145.50 in January to $144.22 in February, they raised it to $144.71 in March.

To learn about the key growth drivers and risks for Johnson & Johnson this year, read Here Are Some Possible Headwinds and Tailwinds for JNJ in 2019.

Analysts Are Divided on Johnson & Johnson Stock

Of the 18 analysts covering Johnson & Johnson, four analysts have given it “strong buys,” five have given it “buys,” eight have given it “holds,” and only one has given it a “sell.” The highest target price estimate for the company is $160, and the lowest is $123.

On March 18, Johnson & Johnson closed at $137.17, 0.31% lower than its previous closing price, 15.64% higher than its 52-week low of $118.62, and 7.93% lower than its 52-week high of $148.99. The company’s market cap is $366.42 billion.

Based on its closing price on March 18, Johnson & Johnson has reported returns of -1.00% in the last week, 2.13% in the last month, and -7.22% in the last quarter. The company has reported returns of -1.94% in the last half year, 3.09% in the last year, and 6.29% year-to-date.

Revenue and EPS estimates

Analysts expect Johnson & Johnson’s revenue to see YoY (year-over-year) changes of -1.94% to $19.62 billion in the first quarter, -1.93% to $20.43 billion in the second quarter, -0.96% to $20.15 billion in the third quarter, and 2.33% to $20.87 billion in the fourth quarter of 2019. Analysts also expect the company’s non-GAAP (generally accepted accounting principles) EPS to see YoY rises of 2.73% to $2.12 in the first quarter, 9.65% to $2.30 in the second quarter, 4.51% to $2.14 in the third quarter, and 2.28% to $2.01 in the fourth quarter.

Analysts expect Johnson & Johnson’s revenues to see YoY changes of -0.50% to $81.17 billion in 2019, 4.18% to $84.56 billion in 2020, and 4.37% to $88.26 billion in 2021. Analysts also expect the company’s non-GAAP EPS to see YoY rises of 4.93% to $8.58 in 2019, 5.76% to $9.08 in 2020, and 7.55% to $9.76 in 2021.

Latest articles

Marathon Petroleum (MPC) stock has been tumbling in Q3, driven by geopolitical tensions, oil price uncertainty, and weaker refining conditions.

This week, AT&T CEO Randall Stephenson noted that AT&T (T) is on track to reduce its leverage multiple to about 2.5x by the end of this year.

Jeff Bezos announced that Amazon had placed an order of 100,000 electric delivery vans from Michigan-based startup Rivian.

Bad news on the trade war front appears to have led to a fall in the broader US equity markets today. Cannabis ETFs were also trading in the red.

Energy Transfer (ET) stock has recovered in the last two trading sessions after investors hammered it on its plans to acquire SemGroup (SEMG).

Software-as-a-service company Datadog (DDOG) made a smashing debut on Wall Street yesterday. After its IPO, DDOG's shares surged 40% in intraday trading.